Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2024—Bio-Rad Laboratories has announced a partnership with Sysmex America in which Bio-Rad’s Unity Next Peer QC software is now available with Sysmex CA-Series and CS-Series hemostasis systems for the United States.
October 2024—The Digital Pathology Association (DPA) invites you to attend this year’s annual meeting, taking place Nov. 3–5 in Orlando, Fla. The theme for Pathology Visions 2024 is “Decision Digital.”
October 2024—Qiagen has released a new version of its clinical decision support software Qiagen Clinical Insight Interpret. The latest release builds on the advanced artificial intelligence capabilities of QCI Interpret, including AI-derived literature searches and AI-trained phenotype-driven ranking.
October 2024—Bio-Rad Laboratories has launched annexin V conjugated to eight StarBright dyes—SBUV400, SBUV795, SBV440, SBV515, SBV790, SBB675, SBB765, and SBY800. The Annexin V StarBright conjugates support detection of early apoptotic cells by flow cytometry, offering an increased range of fluorophore options, and enable full use of all common laser lines found in flow cytometers such that common viability dye and fluorescent protein emission wavelengths can be avoided. This, combined with the narrow excitation and emission of StarBright dyes, reduces spillover and spreading to provide high-resolution data.
October 2024—Maine Molecular Quality Controls now offers Spotfire RSP Controls for the Biofire Spotfire Respiratory/Sore Throat Panel Mini assay. The controls are intended for use as an external assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of pathogens on all Biofire Spotfire respiratory assays performed on the Spotfire system. The kit contains six positive and six negative controls in 300-µL tubes. Maine Molecular Quality Controls 207-885-1072
October 2024—Johnson & Johnson announced Food and Drug Administration approval of Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
September 2024—Bio-Rad Laboratories has launched its Specialty Immunoassay Plus, a four-level, comprehensive, independent specialty immunoassay quality control designed to monitor the precision of laboratory specialty immunoassay testing procedures. The product is available in barcoded, load-and-go InteliQ and standard vial Liquichek configurations and features clinically relevant analytes such as procalcitonin, interleukin-6, active vitamin B12, anti-TSH receptor, thyroid stimulating immunoglobulins, fructosamine, and others. It also contains optimized vitamin D ranges to support Vitamin D Standardization Program–compliant assays and improved intact parathyroid hormone open-vial stability to minimize QC waste. With the Unity data management software, laboratories can compare results across a large peer group of reporting labs.
September 2024—Roche announced that the FDA has granted emergency use authorization for its Cobas Liat SARS-CoV-2, Influenza A/B, and RSV nucleic acid test for use on the Cobas Liat system. The automated multiplex real-time reverse transcription polymerase chain reaction test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus RNA in anterior nasal and nasopharyngeal swab specimens. Definitive results are generated in 20 minutes.
September 2024—Siemens Healthineers has added the NT‑proBNPII assay to its cardiac test menu on the Atellica Solution to help diagnose heart failure. The assay supports timely patient care with a first result available in 10 minutes. The company offers the NT-proBNPII and B-type natriuretic peptide tests on either the Atellica IM or Atellica CI analyzer.
September 2024—BioMérieux announced that its Biofire Spotfire Respiratory/Sore Throat Panel Mini has received FDA special 510(k) clearance and CLIA waiver.
